---
figid: PMC7160552__OR-43-06-1737-g01
figtitle: Schematic diagram that introduces in detail the molecular mechanisms, clinical
  values and cell phenotypes affected by HOXA11-AS in different tumor types, including
  (A) NSCLC, (B) HCC, (C) glioma, (D) CC, and (E) BC
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Homo sapiens
- Mus musculus
- Danio rerio
pmcid: PMC7160552
filename: OR-43-06-1737-g01.jpg
figlink: pmc/articles/PMC7160552/figure/f2-or-43-06-1737/
number: F2
caption: Schematic diagram that introduces in detail the molecular mechanisms, clinical
  values and cell phenotypes affected by HOXA11-AS in different tumor types, including
  (A) NSCLC, (B) HCC, (C) glioma, (D) CC, and (E) BC. ‘Upregulation’/‘downregulation’
  indicates that the expression level of HOXA11-AS in such a tumor was increased/decreased
  compared with normal tissues. The gray arrows (‘bind’/‘sponge’) indicate that HOXA11-AS
  binds to the promoter region of a gene or, as a sponge, binds to a miRNA. The black
  arrows (‘Inf’) indicate that HOXA11-AS affects the phenotypes and the clinical characteristics
  of the cancer under consideration. The blue (‘Pro’)/green (‘In’) arrows indicate
  the promoting or inhibitory effects on the downstream genes, respectively. The purple
  arrows (‘Reg’) indicate the regulatory effects on the downstream pathway. NSCLC,
  non-small cell lung cancer; HCC, hepatocellular carcinoma; CRC, colorectal cancer;
  BC, breast cancer; HOXA11-AS, HOXA11 antisense RNA.
papertitle: Recent advances in unraveling the molecular mechanisms and functions of
  HOXA11-AS in human cancers and other diseases.
reftext: Cheng Wei, et al. Oncol Rep. 2020 Jun;43(6):1737-1754.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8164762
figid_alias: PMC7160552__F2
figtype: Figure
redirect_from: /figures/PMC7160552__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7160552__OR-43-06-1737-g01.html
  '@type': Dataset
  description: Schematic diagram that introduces in detail the molecular mechanisms,
    clinical values and cell phenotypes affected by HOXA11-AS in different tumor types,
    including (A) NSCLC, (B) HCC, (C) glioma, (D) CC, and (E) BC. ‘Upregulation’/‘downregulation’
    indicates that the expression level of HOXA11-AS in such a tumor was increased/decreased
    compared with normal tissues. The gray arrows (‘bind’/‘sponge’) indicate that
    HOXA11-AS binds to the promoter region of a gene or, as a sponge, binds to a miRNA.
    The black arrows (‘Inf’) indicate that HOXA11-AS affects the phenotypes and the
    clinical characteristics of the cancer under consideration. The blue (‘Pro’)/green
    (‘In’) arrows indicate the promoting or inhibitory effects on the downstream genes,
    respectively. The purple arrows (‘Reg’) indicate the regulatory effects on the
    downstream pathway. NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma;
    CRC, colorectal cancer; BC, breast cancer; HOXA11-AS, HOXA11 antisense RNA.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HOXA11-AS
  - PDE4D
  - CBLIF
  - MIR200B
  - TGFB1
  - TGFB2
  - TGFB3
  - DOCK8
  - INTU
  - STAT3
  - ITK
  - SLC22A3
  - TENM1
  - HCC
  - HYCC1
  - HOXA2
  - CDK4
  - CCNE1
  - CCNE2
  - CDK2
  - LATS1
  - DUSP5
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - CDKN2A
  - H3P10
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - EZH2
  - CXCR1
  - CDH1
  - FZR1
  - PADI2
  - CEACAM5
  - CEACAM3
  - PSG2
  - Hoxa11os
  - Pde4d
  - Cblif
  - Mir200b
  - Tgfb1
  - Ltbp1
  - Dock8
  - Spin2g
  - Stat3
  - Itk
  - Slc22a3
  - Hoxa2
  - Cdk4
  - Cdk2
  - Lats1
  - Dusp5
  - Cdkn1a
  - Nsg1
  - Tpt1
  - Tceal1
  - Cdkn2a
  - Cyp2b10
  - Rbm14
  - Cdkn1b
  - Dctn6
  - Psmd9
  - Ezh2
  - Ccr8
  - Cdh1
  - Fzr1
  - Padi2
  - Cea
  - pde4d
  - mir200b
  - dock8
  - stat3
  - hccsa.2
  - hoxa2b
  - cdk4
  - cdk2
  - lats1
  - dusp5
  - cdkn1a
  - cdkn2a/b
  - ezh2
  - cdh1
  - si:busm1-180o5.1
  - si:busm1-180o5.2
  - padi2
  - cisplatin
  - Non-small-cell lung cancer
  - NSCLC
  - tumor
  - Hepatocellular carcinoma
  - Glioma
  - Colorectal cancer
  - Breast cancer
---
